Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.15M Buy
8,956
+6,781
+312% +$794K 0.22% 71
2026
Q1
$262K Sell
2,175
-313
-13% -$36.1K 0.02% 159
2025
Q4
$262K Sell
2,488
-198
-7% -$18.6K 0.02% 165
2025
Q3
$225K Sell
2,686
-83
-3% -$6.84K 0.02% 174
2025
Q2
$219K Sell
2,769
-3,660
-57% -$291K 0.02% 162
2025
Q1
$577K Buy
6,429
+97
+2% +$9.06K 0.07% 85
2024
Q4
$630K Buy
6,332
+71
+1% +$7.32K 0.09% 70
2024
Q3
$711K Buy
6,261
+1,565
+33% +$186K 0.12% 67
2024
Q2
$601K Buy
4,696
+1,387
+42% +$179K 0.12% 75
2024
Q1
$433K Buy
3,309
+699
+27% +$86.2K 0.09% 63
2023
Q4
$285K Buy
+2,610
New +$271K 0.07% 86

Other funds holding MRK

49 Wealth Management's MRK Position: Q2 2026 in Review

49 Wealth Management increased its Merck (MRK) stake by 312% in Q2 2026, buying an estimated $794K and bringing the position to 8,956 shares worth $1.15M. The position accounts for 0.22% of the portfolio, ranked #71.

49 Wealth Management first reported a position in MRK in Q4 2023 and has held it in 11 quarters since. 3,836 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • 49 Wealth Management held 8,956 shares of Merck worth $1.15M as of Q2 2026.
  • 49 Wealth Management bought 6,781 Merck shares in Q2 2026, an estimated $794K.
  • Merck made up 0.22% of 49 Wealth Management's portfolio in Q2 2026, its #71 holding.
  • 49 Wealth Management first reported a position in Merck in Q4 2023 and has held it in 11 quarters since.
  • 3,836 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on 49 Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.